MX2023012608A - Virus oncoliticos para la expresion modificada del mhc. - Google Patents

Virus oncoliticos para la expresion modificada del mhc.

Info

Publication number
MX2023012608A
MX2023012608A MX2023012608A MX2023012608A MX2023012608A MX 2023012608 A MX2023012608 A MX 2023012608A MX 2023012608 A MX2023012608 A MX 2023012608A MX 2023012608 A MX2023012608 A MX 2023012608A MX 2023012608 A MX2023012608 A MX 2023012608A
Authority
MX
Mexico
Prior art keywords
oncolytic viruses
mhc expression
modified mhc
major histocompatibility
histocompatibility complex
Prior art date
Application number
MX2023012608A
Other languages
English (en)
Spanish (es)
Inventor
Stephen Howard Thorne
Mingrui Zhang
Original Assignee
Kalivir Immunotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalivir Immunotherapeutics Inc filed Critical Kalivir Immunotherapeutics Inc
Publication of MX2023012608A publication Critical patent/MX2023012608A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/065—Poxviridae, e.g. avipoxvirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2023012608A 2021-04-30 2022-04-28 Virus oncoliticos para la expresion modificada del mhc. MX2023012608A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163182243P 2021-04-30 2021-04-30
PCT/US2022/026703 WO2022232375A1 (en) 2021-04-30 2022-04-28 Oncolytic viruses for modified mhc expression

Publications (1)

Publication Number Publication Date
MX2023012608A true MX2023012608A (es) 2023-11-03

Family

ID=83848828

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2023012608A MX2023012608A (es) 2021-04-30 2022-04-28 Virus oncoliticos para la expresion modificada del mhc.
MX2024007787A MX2024007787A (es) 2021-04-30 2023-10-24 Virus oncoliticos para la expresion modificada del mhc.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024007787A MX2024007787A (es) 2021-04-30 2023-10-24 Virus oncoliticos para la expresion modificada del mhc.

Country Status (19)

Country Link
US (4) US12016893B2 (https=)
EP (1) EP4329786A4 (https=)
JP (1) JP2024516400A (https=)
KR (1) KR20240004764A (https=)
CN (1) CN117241813A (https=)
AU (1) AU2022265689A1 (https=)
BR (1) BR112023022681A2 (https=)
CA (1) CA3215344A1 (https=)
CL (2) CL2023003199A1 (https=)
CO (1) CO2023014507A2 (https=)
CR (1) CR20230551A (https=)
DO (1) DOP2023000233A (https=)
EC (1) ECSP23081932A (https=)
IL (2) IL308018B2 (https=)
JO (1) JOP20230257A1 (https=)
MX (2) MX2023012608A (https=)
PE (1) PE20250454A1 (https=)
TW (1) TW202305125A (https=)
WO (1) WO2022232375A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115927471A (zh) * 2022-11-23 2023-04-07 郑州大学 A49r基因缺失的溶瘤痘苗病毒载体的构建方法及应用
KR20250121414A (ko) * 2022-12-15 2025-08-12 칼리버 임뮤노쎄라퓨틱스, 인크. Cd47/sirp-알파 면역 체크포인트 억제제 조성물 및 그의 용도
WO2025184411A1 (en) * 2024-02-27 2025-09-04 Calidi Biotherapeutics (Nevada), Inc. Serum-resistant eev viruses and uses thereof
WO2025199630A1 (en) * 2024-03-27 2025-10-02 Genvira Biosciences Inc. Viruses for inducing antigen presentation

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4409450A (en) 1982-07-29 1983-10-11 Amp Incorporated Double pole membrane switch having preferred sequence closing feature
ZA842025B (en) 1983-03-21 1984-11-28 Hoffmann La Roche Interleuken-2
FR2573436B1 (fr) 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
CA2130578A1 (en) 1992-04-17 1993-10-28 Geewananda P. Gunawardana Taxol derivatives
EP1024198A3 (en) 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
SK282843B6 (sk) 1993-07-13 2002-12-03 Rhone-Poulenc Rorer S. A. Defektný rekombinantný adenovírus a farmaceutický prostriedok s jeho obsahom
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US5912264A (en) 1997-03-03 1999-06-15 Bristol-Myers Squibb Company 6-halo-or nitrate-substituted paclitaxels
JP4139860B2 (ja) 1997-11-10 2008-08-27 ストラカン インターナショナル リミティッド 浸透増強および刺激減少システム
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AT406376B (de) 1998-01-16 2000-04-25 Immuno Ag Chimäres poxvirus enthaltend eine retrovirale vektorkomponente
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
US6198323B1 (en) 1999-01-28 2001-03-06 Lucent Technologies Inc. Flip-flop having gated inverter feedback structure with embedded preset/clear logic
US20040214783A1 (en) 2002-05-08 2004-10-28 Terman David S. Compositions and methods for treatment of neoplastic disease
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6967023B1 (en) 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
CO5280224A1 (es) 2000-02-02 2003-05-30 Univ Florida State Res Found Taxanos sustituidos con ester en c7, utiles como agentes antitumorales y composiciones farmaceuticas que los contienen
DK1263936T3 (da) 2000-03-14 2006-02-13 Bavarian Nordic As andret stamme af den modificerede Vacciniavirus Ankara (MVA)
EP1272630A2 (en) 2000-03-16 2003-01-08 Genetica, Inc. Methods and compositions for rna interference
ES2254408T4 (es) 2000-04-25 2007-10-01 Immunex Corporation Procedimiento de tratamiento de tumores usando terapia fotodinamica.
US7179483B2 (en) 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
JP4845327B2 (ja) 2000-07-21 2011-12-28 千葉県 腫瘍特異的プロモーター
AU2002211490A1 (en) 2000-10-04 2002-04-15 The Trustees Of The University Of Pennsylvania Compositions and methods of using capsid protein from flaviviruses and pestiviruses
EP1213025A1 (de) 2000-12-06 2002-06-12 Laboratoires Serobiologiques(Societe Anonyme) Kosmetische und/oder dermopharmazeutische Zubereitungen enthaltend Extrakte aus den Blättern der Pflanze Argania spinosa
EP1341817A2 (en) 2000-12-08 2003-09-10 Novo Nordisk A/S Tff peptides
ATE437221T1 (de) 2001-05-14 2009-08-15 Gbp Ip Llc Lentivirale vektoren kodierend für gerinnungsfaktoren für die gentherapie
JP2003009883A (ja) 2001-07-05 2003-01-14 Mitsubishi Pharma Corp マスト細胞の細胞死誘発剤
WO2003035683A2 (en) 2001-10-26 2003-05-01 Uffe Holmskov Surfactant protein-d and atherosclerosis
US7368122B1 (en) 2002-03-08 2008-05-06 Dow Pharmaceutical Sciences Skin cream
KR20120002613A (ko) 2002-08-12 2012-01-06 제네렉스, 인코포레이티드 폭스바이러스 및 암과 관련된 방법 및 조성물
EP2186811A1 (en) 2002-08-23 2010-05-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20040143026A1 (en) 2002-12-31 2004-07-22 Shah Kishore R. Bioadhesive hydrophilic composition for treatment of mammalian skin
NZ570709A (en) 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
AU2004272607B2 (en) 2003-09-11 2008-11-06 Cornerstone Therapeutics Inc. Monoclonal antibodies against HMGB1
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
WO2005054451A1 (ja) 2003-12-05 2005-06-16 Hokkaido Technology Licensing Office Co., Ltd. 高度安全性痘瘡ワクチンウイルスおよびワクシニアウイルスベクター
DE102004030044A1 (de) 2004-06-22 2006-01-12 Birken Gmbh Triterpenhaltiger Oleogelbildner, triterpenhaltiges Oleogel und Verfahren zur Herstellung eines triterpenhaltigen Oleogels
US8007806B2 (en) 2005-01-20 2011-08-30 Isconova Ab Vaccine composition comprising a fibronectin binding protein or a fibronectin binding peptide
DK2062023T4 (en) 2006-08-25 2017-02-20 The Government Of The Us Secretary Dept Of Health And Human Services INTERGENIC SITES BETWEEN CONSERVATED GENES THROUGH MODIFIED VACCINIA ANKARA (VAT) VACCINIAVIRUS
WO2008023077A2 (en) 2006-08-25 2008-02-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Compositions and methods for modulating an immune response
EP2097517B1 (en) * 2006-10-16 2014-06-04 Genelux Corporation Recombinant Lister strain vaccinia virus encoding an anti-VEGF single chain antibody
GB0702695D0 (en) 2007-02-12 2007-03-21 Ark Therapeutics Ltd Production of vectors
US8003363B2 (en) 2007-05-14 2011-08-23 Bavarian Nordic A/S Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
ES2560871T3 (es) 2007-07-10 2016-02-23 Apogenix Gmbh Proteínas de fusión de colectina de la superfamilia de TNF
SI4269578T1 (sl) 2008-03-06 2024-07-31 Halozyme, Inc. Sestava topne hialuronidaze
ES2532896T5 (es) * 2008-05-14 2018-03-20 Immatics Biotechnologies Gmbh Péptidos del MHC de clase II novedosos y potentes derivados de survivina y neurocan
EP2349296B1 (en) 2008-08-21 2017-04-05 Ottawa Hospital Research Institute Engineered synergistic oncolytic viral symbiosis
CN101381742A (zh) 2008-10-23 2009-03-11 浙江理工大学 晚期启动子靶向性调控溶瘤腺病毒pCN305载体及其构建方法与应用
EP2184297A1 (en) 2008-11-07 2010-05-12 Hla-G Technologies HLA-G polypeptides and pharmaceutical uses thereof
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
CA2709292A1 (en) 2009-07-10 2011-01-10 The Governors Of The University Of Alberta Oncolytic viruses and methods for treating neoplastic disorders
JP5686814B2 (ja) 2010-09-17 2015-03-18 独立行政法人科学技術振興機構 Ｈｍｇｂタンパクによって仲介される免疫応答の活性化の抑制剤及びスクリーニング方法
WO2012089225A1 (en) * 2010-12-29 2012-07-05 Curevac Gmbh Combination of vaccination and inhibition of mhc class i restricted antigen presentation
AU2012204467B2 (en) 2011-01-04 2016-08-18 Sillajen, Inc. Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
ES2733211T3 (es) * 2011-04-15 2019-11-28 Genelux Corp Cepas clonales de virus vaccinia atenuados y métodos de uso de las mismas
EP2739293B1 (en) 2011-08-05 2020-06-10 SillaJen Biotherapeutics, Inc. Methods and compositions for production of vaccina virus
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP3473708B1 (en) 2012-07-24 2021-01-27 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
DK2986311T3 (en) 2013-04-18 2019-02-25 Tilt Biotherapeutics Oy IMPROVED ADOPTIVE CELL THERAPY
KR102322510B1 (ko) * 2013-07-18 2021-11-08 브이아이비 브이지더블유 수용체 결합친화성이 현격히 감소된 사이토카인을 수반하는 푸소카인
RS65104B1 (sr) 2013-08-22 2024-02-29 Univ Pittsburgh Commonwealth Sys Higher Education Onkolitičke imunoterapije
US10238700B2 (en) 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
MA39818A (fr) * 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
US20160060311A1 (en) 2014-08-27 2016-03-03 Daewoong Jo Development of Protein-Based Biotherapeutics That Penetrates Cell-Membrane and Induces Anti-Lung Cancer Effect - Improved Cell-Permeable Suppressor of Cytokine Signaling (iCP-SOCS3) Proteins, Polynucleotides Encoding the Same, and Anti-Lung Cancer Compositions Comprising the Same
PT3186281T (pt) 2014-08-28 2019-07-10 Halozyme Inc Terapia de combinação com uma enzima de degradação de hialuronano e um inibidor de pontos de verificação imunológica
BR112017007765B1 (pt) 2014-10-14 2023-10-03 Halozyme, Inc Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
EP3217993A1 (en) 2015-07-20 2017-09-20 Virttu Biologics Limited Treatment of cancer by infusion of oncolytic herpes simplex virus to the blood
WO2017043815A1 (en) 2015-09-08 2017-03-16 Sillajen, Inc. Modified oncolytic vaccinia viruses expressing a cytokine and a car- boxylesterase and methods of use thereof
KR20180133395A (ko) 2016-02-25 2018-12-14 메모리얼 슬로안 케터링 캔서 센터 암 면역요법을 위한, 인간 flt3l 또는 gm-csf의 발현이 있거나 없으며 티미딘 키나제가 결실된 복제 가능 약독화 백시니아 바이러스
WO2017165464A1 (en) 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
US20180000733A1 (en) 2016-06-30 2018-01-04 Ava, Inc. Safe and stable antiseptic solution comprising chlorhexidine
AU2017332367B2 (en) 2016-09-21 2021-12-23 Stephen H. Thorne High mobility group box i mutant
WO2018058258A1 (en) 2016-09-30 2018-04-05 University Health Network Recombinant oncolytic viruses for cancer therapy
WO2018091680A1 (en) * 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
US11185586B2 (en) 2016-11-22 2021-11-30 Alloplex Biotherapeutics, Inc. Allogeneic tumor cell vaccine
KR20190112263A (ko) * 2016-12-12 2019-10-04 멀티비르 인코포레이티드 암 및 감염성 질환의 치료 및 예방을 위한 바이러스 유전자 치료요법 및 면역 체크포인트 억제제를 포함하는 방법 및 조성물
WO2019055860A1 (en) * 2017-09-15 2019-03-21 The Texas A&M University System METHODS FOR IMPROVING IMMUNOTHERAPY IN THE TREATMENT OF CANCER
EP3703723A4 (en) * 2017-10-31 2021-12-15 KaliVir Immunotherapeutics, Inc. ONCOLYTIC PLATFORM VECTOR FOR SYSTEMS ADMINISTRATION
EP3735467A4 (en) * 2018-01-05 2021-12-01 Ottawa Hospital Research Institute MODIFIED VACCINE VECTORS
WO2019148109A1 (en) 2018-01-26 2019-08-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Expression of metabolic modulators in tumor microenvironment to improve tumor therapy
EP3788142A4 (en) * 2018-05-02 2022-04-27 Tonix Pharma Holdings Limited SYNTHETIC CHIMERIC VACCINE VIRUS
MX2021003013A (es) * 2018-09-15 2021-08-11 Memorial Sloan Kettering Cancer Center Poxvirus recombinantes para inmunoterapia contra cáncer.
CA3116192C (en) * 2018-11-06 2025-09-23 Calidi Biotherapeutics (Nevada), Inc. IMPROVED SYSTEMS FOR CELL-MEDIATED ONCOLYTIC VIRAL THERAPY
JP2022524951A (ja) * 2019-02-27 2022-05-11 アクティム・セラピューティクス・インコーポレイテッド 腫瘍、腫瘍常在免疫細胞および腫瘍微小環境にコロニー形成するよう操作した免疫刺激性細菌

Also Published As

Publication number Publication date
US20230263846A1 (en) 2023-08-24
IL308018B1 (en) 2024-12-01
TW202305125A (zh) 2023-02-01
EP4329786A4 (en) 2024-12-11
IL316712B1 (en) 2025-08-01
BR112023022681A2 (pt) 2024-01-23
JP2024516400A (ja) 2024-04-15
CO2023014507A2 (es) 2023-11-10
AU2022265689A1 (en) 2023-10-19
US20230338445A1 (en) 2023-10-26
PE20250454A1 (es) 2025-02-19
JOP20230257A1 (ar) 2023-10-17
IL316712B2 (en) 2025-12-01
US20240277794A1 (en) 2024-08-22
CL2024002377A1 (es) 2024-11-08
CA3215344A1 (en) 2022-11-03
IL308018A (en) 2023-12-01
IL316712A (en) 2024-12-01
US12016893B2 (en) 2024-06-25
CR20230551A (es) 2024-05-07
MX2024007787A (es) 2024-07-09
CL2023003199A1 (es) 2024-04-05
WO2022232375A1 (en) 2022-11-03
US20240277793A1 (en) 2024-08-22
US11963990B2 (en) 2024-04-23
CN117241813A (zh) 2023-12-15
EP4329786A1 (en) 2024-03-06
IL308018B2 (en) 2025-04-01
ECSP23081932A (es) 2023-11-30
KR20240004764A (ko) 2024-01-11
DOP2023000233A (es) 2023-12-15

Similar Documents

Publication Publication Date Title
MX2024007787A (es) Virus oncoliticos para la expresion modificada del mhc.
BR112022000641A2 (pt) Modificação genética de célula efetora imune e uso da mesma
MX2024002353A (es) Celulas asesinas naturales modificadas geneticamente.
BR112021022666A2 (pt) Frações de separação e seus métodos e uso
EP4403229A3 (en) Expression of pten-long with oncolytic viruses
AU2016262093A8 (en) Enhancing endonuclease based gene editing in primary cells
MX2020009896A (es) Celulas efectoras inmunitarias modificadas y usos de las mismas.
BR112013002811A8 (pt) meios básicos simplificados para cultura celular pluripotente de humano
CO6680636A2 (es) Método para producir adamts13 recombinante en cultivo celular
BR112018067536A2 (pt) sistema de transpóson e métodos de uso
CA2866116C (en) Expansion of alloantigen-reactive regulatory t cells
CL2023001860A1 (es) Composiciones y métodos para reducir hla-a en una célula
BR112014023572A2 (pt) método para tratar ou prevenir dano de articulação em um indivíduo com ra precoce ou ra incipiente, uso de um agente ou combinação de agentes que estimulam uma resposta tolerogênica específica de antígeno a um polipeptídeo de agrecan, e agente ou combinação de agentes
EA202191257A1 (ru) Противораковая терапия на основе иммуноцитов, связывающих liv1
BR112018010499A8 (pt) método para replicar um vírus, vírus, método para produzir uma composição de vacina, composição de vacina, população de células in vitro, método para produzir uma população de células, e população de células
WO2020055932A3 (en) Methods of treating immunotherapy-related toxicity using a gm-csf antagonist
ECSP19090449A (es) Composiciones y métodos para incrementar la vida útil del banano
MX2018011162A (es) Metodos de purificacion de colageno 7.
WO2021178833A3 (en) Designed il-2 variants
CL2010000774A1 (es) Medio para el cultivo de celulas de mamiferos que comprende ademas de los nutrientes habituales de los medios de cultivo basales para cultivo de celulas de mamiferos, sobrenadante de la fraccion ii+iii del plasma humano segun el metodo de cohn; procedimiento de preparacion; y su uso.
SG10201901391RA (en) Induction of il-12 using immunotherapy
WO2022006306A3 (en) Compositions for genome editing and methods of use thereof
MX2021005564A (es) Metodos y composiciones para inmunoterapia contra cancer.
BR112021017057A2 (pt) Células, composições e métodos para intensificar a função imune
BR112023023386A2 (pt) Células engenheiradas para produção aumentada de proteínas de difícil expressão